๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 18 Guangzhou 18 Beijing 15 Changsha 10 Hangzhou 8
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai18 Guangzhou18 Beijing15 Changsha10 Hangzhou8
All 39 locations
Target enrolment
to

Trials with a site in Beijing

15 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
YSCH-01 Via Nebulization in Pulmonary Metastasis of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC)
NCT07793500NSCLC, Advanced Solid Tumor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase EARLY_PHASE1
36
Beijing
2025-11-27
Not yet open
A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC
NCT07086326NSCLC, Neoadjuvant Therapy, Immunotherapy, AK112
Yang Fan, MD
Phase 2
164
Beijing, Changsha, Shanghai, Xiโ€™an, Hangzhou
2025-07-31
Recruiting
Adaptive Therapy for Resected Stage โ… A2-โ…ก NSCLC Patients With Undetectable MRD
NCT06924710NSCLC
Peking University Cancer Hospital & Institute
Not applicable
286
Beijing
2025-04-06
Recruiting
A Phase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC
NCT06844474NSCLC
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2
300
Beijing
2025-03-07
Recruiting
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
NCT06422143Non-small Cell Lung Cancer, NSCLC
Merck Sharp & Dohme LLC
Phase 3
851
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Wuhan
2024-06-10
Recruiting
Real-world Clinical Outcomes of NSCLC Patients Receiving Neoadjuvant Immunotherapy
NCT06317558NSCLC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
4,000
Beijing
2024-03-01
Recruiting
A Study of YL202 in Selected Patients With Advanced Solid Tumors
NCT06107686NSCLC, Breast Cancer, HNSCC, Locally Advanced or Metastatic Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 2
200
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Meizhou, Shantou, Guilin
2023-12-15
Recruiting
Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC
NCT07247227NSCLC
Peking Union Medical College
Not applicable
150
Beijing
2023-10-10
Recruiting
TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
NCT05948813NSCLC, EGFR Activating Mutation, Brain Metastases
TYK Medicines, Inc
Phase 2
420
Beijing
2023-08-17
Recruiting
Phase I Study of HSK40118 in NSCLC Patients With EGFR Mutation
NCT06050980NSCLC
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
220
Beijing, Chongqing, Fuzhou, Nanning, Harbin, Luoyang, Zhengzhou, Changsha
2023-03-27
Active, closed
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
NCT05687266NSCLC
AstraZeneca
Phase 3
1,350
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hefei, Jinan, Kunming
2022-12-29
Active, closed
Lorlatinib Continuation Study
NCT05144997Non-Small-Cell Lung Cancer, NSCLC
Pfizer
Phase 4
76
Hefei, Beijing, Fuzhou, Guangzhou, Changsha, Nanjing, Changchun, Hangzhou
2021-12-28
Active, closed
Crizotinib Continuation Clinical Study
NCT05160922NSCLC, ALCL, IMT
Pfizer
Phase 4
27
Beijing, Fuzhou, Guangzhou, Changchun, Wuhou District, Hangzhou, Shanghai
2021-12-27
Active, closed
A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China
NCT05009329NSCLC, Solid Tumor
Allist Pharmaceuticals, Inc.
Phase 1/2
315
Beijing
2021-07-26
Rows per page Showing 1–15 of 15
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 15 of those studies with a site in Beijing that also match the filters currently applied.

How many clinical trials are recruiting in Beijing?

10 of the 15 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 4 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Beijing), 15 studies
PhaseStudiesRecruitingShare
Phase 24326.7%
Phase 33220%
Not applicable2213.3%
Phase 42013.3%
Observational116.7%
Phase 1116.7%
Phase 1/2106.7%
Phase EARLY_PHASE1116.7%

Most active sponsors

Lead sponsors with the most studies (Beijing)
Lead sponsorStudiesRecruiting
Allist Pharmaceuticals, Inc.21
Cancer Institute and Hospital, Chinese Academy of Medical Sciences22
Pfizer20
AstraZeneca10
Haisco Pharmaceutical Group Co., Ltd.11
MediLink Therapeutics (Suzhou) Co., Ltd.11
Merck Sharp & Dohme LLC11
Peking Union Medical College11
Peking University Cancer Hospital & Institute11
Suzhou Suncadia Biopharmaceuticals Co., Ltd.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.